Glenmark Pharma’s arm to launch Sodium Bicarbonate Injection USP

04 Nov 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., (Glenmark) is all set to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark’s 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA. Glenmark will begin distribution in November 2025.

According to IQVIA sales data for the 12-month period ending August 2025, the 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) market achieved annual sales of approximately $63.8 million. Glenmark’s 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma Share Price

1959.00 -15.15 (-0.77%)
05-Dec-2025 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1521.50
Zydus Lifesciences 933.10
Lupin 2089.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×